Pfizer Forecast, price target & analysts
Pfizer Target price 2025 - Analyst rating & recommendation
Pfizer Classifications & Recommendation:
Pfizer Price Target
| Target Price | $28.94 |
| Price | $22.14 |
| Potential |
30.72%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Pfizer 2026 .
The average Pfizer target price is $28.94.
This is
30.72%
register free of charge
$35.00
58.08%
register free of charge
$23.00
3.88%
register free of charge
|
|
| A rating was issued by 23 analysts: 8 Analysts recommend Pfizer to buy, 14 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pfizer stock has an average upside potential 2026 of
30.72%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 63.63 | 62.90 |
| 6.84% | 1.14% | |
| EBITDA Margin | 36.93% | 38.53% |
| 89.88% | 4.34% | |
| Net Margin | 12.56% | 18.95% |
| 256.68% | 50.90% |
18 Analysts have issued a sales forecast Pfizer 2025 . The average Pfizer sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Pfizer EBITDA forecast 2025. The average Pfizer EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Pfizer Analysts have issued a net profit forecast 2025. The average Pfizer net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.41 | 2.10 |
| 281.08% | 48.94% | |
| P/E | 10.53 | |
| EV/Sales | 2.74 |
5 Analysts have issued a Pfizer forecast for earnings per share. The average Pfizer EPS is
This results in the following potential growth metrics and future valuations:
Current Pfizer Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 10 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 18 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 10 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jan 28 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Jan 08 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
